-
Something wrong with this record ?
The impact of standard chemotherapy on miRNA signature in plasma in AML patients
L. Koutova, M. Sterbova, E. Pazourkova, S. Pospisilova, I. Svobodova, A. Horinek, D. Lysak, M. Korabecna,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Validation Study
Persistent link
https://www.medvik.cz/link/bmc16009975
- MeSH
- Leukemia, Myeloid, Acute blood drug therapy genetics MeSH
- Cytarabine administration & dosage MeSH
- Adult MeSH
- Idarubicin administration & dosage MeSH
- Remission Induction MeSH
- Consolidation Chemotherapy MeSH
- Real-Time Polymerase Chain Reaction MeSH
- Middle Aged MeSH
- Humans MeSH
- MicroRNAs biosynthesis blood genetics MeSH
- Mitoxantrone administration & dosage MeSH
- Pilot Projects MeSH
- Antineoplastic Combined Chemotherapy Protocols pharmacology therapeutic use MeSH
- Gene Expression Regulation, Leukemic drug effects MeSH
- RNA, Neoplasm biosynthesis blood genetics MeSH
- Transcriptome * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Validation Study MeSH
AIM: In our pilot study, we used plasma samples as liquid biopsy to search for miRNA signatures in patients with acute myeloid leukemia (AML) at diagnosis and in remission achieved after standard chemotherapy before planned transplantation. MATERIAL AND METHODS: We examined 10 plasma samples from healthy volunteers and 8 paired samples from patients with AML at diagnosis and in remission using TaqMan MicroRNA Arrays. The results were validated using single-target qPCR reactions run in triplicates. RESULTS: We selected 6 miRNAs with expressions significantly sensitive to therapy: miR-199b-5p, miR-301b, miR-326, miR-361-5p, miR-625 and miR-655. All selected miRNAs were not or very weakly expressed in healthy individuals. They were abundant in plasma in patients at diagnosis but their levels decreased after chemotherapy. CONCLUSION: We detected a therapy sensitive miRNA signature in plasma of patients with AML.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16009975
- 003
- CZ-PrNML
- 005
- 20161214100025.0
- 007
- ta
- 008
- 160408s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2015.08.009 $2 doi
- 024 7_
- $a 10.1016/j.leukres.2015.08.009 $2 doi
- 035 __
- $a (PubMed)26340914
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Koutova, Linda $u Department of Hematoonocology, Charles University Hospital in Pilsen, Alej Svobody 80, 304 60 Pilsen, Czech Republic.
- 245 14
- $a The impact of standard chemotherapy on miRNA signature in plasma in AML patients / $c L. Koutova, M. Sterbova, E. Pazourkova, S. Pospisilova, I. Svobodova, A. Horinek, D. Lysak, M. Korabecna,
- 520 9_
- $a AIM: In our pilot study, we used plasma samples as liquid biopsy to search for miRNA signatures in patients with acute myeloid leukemia (AML) at diagnosis and in remission achieved after standard chemotherapy before planned transplantation. MATERIAL AND METHODS: We examined 10 plasma samples from healthy volunteers and 8 paired samples from patients with AML at diagnosis and in remission using TaqMan MicroRNA Arrays. The results were validated using single-target qPCR reactions run in triplicates. RESULTS: We selected 6 miRNAs with expressions significantly sensitive to therapy: miR-199b-5p, miR-301b, miR-326, miR-361-5p, miR-625 and miR-655. All selected miRNAs were not or very weakly expressed in healthy individuals. They were abundant in plasma in patients at diagnosis but their levels decreased after chemotherapy. CONCLUSION: We detected a therapy sensitive miRNA signature in plasma of patients with AML.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
- 650 _2
- $a konsolidační chemoterapie $7 D060830
- 650 _2
- $a cytarabin $x aplikace a dávkování $7 D003561
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u leukemie $x účinky léků $7 D015973
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a idarubicin $x aplikace a dávkování $7 D015255
- 650 _2
- $a akutní myeloidní leukemie $x krev $x farmakoterapie $x genetika $7 D015470
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x biosyntéza $x krev $x genetika $7 D035683
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mitoxantron $x aplikace a dávkování $7 D008942
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a RNA nádorová $x biosyntéza $x krev $x genetika $7 D012334
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 650 _2
- $a indukce remise $7 D012074
- 650 12
- $a transkriptom $7 D059467
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a validační studie $7 D023361
- 700 1_
- $a Sterbova, Monika $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic.
- 700 1_
- $a Pazourková, Eva $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic. $7 xx0208969
- 700 1_
- $a Pospisilova, Sarka $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic.
- 700 1_
- $a Svobodova, Iveta $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic.
- 700 1_
- $a Horinek, Ales $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic.
- 700 1_
- $a Lysak, Daniel $u Department of Hematoonocology, Charles University Hospital in Pilsen, Alej Svobody 80, 304 60 Pilsen, Czech Republic.
- 700 1_
- $a Korabecna, Marie $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic; Medical Faculty in Pilsen, Charles University in Prague, Husova 3, 306 05 Pilsen, Czech Republic. Electronic address: marie.korabecna@lf1.cuni.cz.
- 773 0_
- $w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 39, č. 12 (2015), s. 1389-95
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26340914 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20161214100043 $b ABA008
- 999 __
- $a ok $b bmc $g 1113404 $s 934343
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 39 $c 12 $d 1389-95 $e 20150820 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
- LZP __
- $a Pubmed-20160408
